CAR T-cell therapy: Reprogramming patient's immune cell to treat cancer.

Chimeric antigen receptor (CAR)-T cell therapy is a game changer in cancer treatment. Although CAR-T cell therapy has achieved significant clinical responses in specific subgroups of B cell leukaemia or lymphoma, various difficulties restrict CAR-T cell therapy's therapeutic effectiveness in solid tumours and haematological malignancies. Severe life-threatening toxicities, poor anti-tumour effectiveness, antigen escape, restricted trafficking, and limited tumour penetration are all barriers to successful CAR-T cell treatment. Furthermore, CAR-T cell interactions with the host and tumour microenvironment have a significant impact on their activity. Furthermore, developing and implementing these therapies necessitates a complicated staff. Innovative methodologies and tactics to engineering more potent CAR-T cells with greater anti-tumour activity and less toxicity are required to address these important difficulties.

• Publication year

  2023

• Venue

  Cellular Signalling

• Publication date

  2023-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.cellsig.2023.110638PMID 36822565
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy

  2020cited by this paper
• Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

  2020cited by this paper
• Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma

  2020cited by this paper
• CXCR2‐modified CAR‐T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma

  2020cited by this paper
• Amendment history : Expression of Concern ( July 2019 ) Tandem CAR T cells targeting HER 2 and IL 13 R a 2 mitigate tumor antigen escape

  2019cited by this paper
• ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

  2019cited by this paper
• CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors

  2019cited by this paper
• A safe and potent anti-CD19 CAR T cell therapy

  2019cited by this paper
• Using CuO nanoparticles and hyperthermia in radiotherapy of MCF-7 cell line: synergistic effect in cancer therapy

  2019cited by this paper
• CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors

  2019cited by this paper
• Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.

  2019cited by this paper
• Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies.

  2019cited by this paper
• Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches.

  2019cited by this paper
• B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.

  2019cited by this paper
• Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy

  2019cited by this paper
• Recent updates on CAR T clinical trials for multiple myeloma

  2019cited by this paper
• Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors.

  2019cited by this paper
• A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma

  2019cited by this paper
• Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies

  2019cited by this paper
• Engineering strategies to overcome the current roadblocks in CAR T cell therapy

  2019cited by this paper
• Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies

  2018cited by this paper
• Enhanced Safety and Efficacy of Oncolytic VSV Therapy by Combination with T Cell Receptor Transgenic T Cells as Carriers

  2018cited by this paper
• Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells

  2018cited by this paper
• Interferon gamma in cancer immunotherapy

  2018cited by this paper
• Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.

  2018cited by this paper
• Tumor Antigen Escape from CAR T-cell Therapy.

  2018cited by this paper
• Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.

  2018cited by this paper
• T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.

  2018cited by this paper
• Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas

  2018cited by this paper
• CAR T cell immunotherapy for human cancer

  2018cited by this paper
• Cancer immunotherapy using checkpoint blockade

  2018cited by this paper
• Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication.

  2018cited by this paper
• Glycan-directed CAR-T cells

  2018cited by this paper
• The Pharmacology of T Cell Therapies

  2018cited by this paper
• Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function

  2018cited by this paper
• Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma

  2018cited by this paper
• Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

  2018cited by this paper
• Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

  2018cited by this paper
• Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.

  2018cited by this paper
• Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia

  2018cited by this paper
• Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.

  2017cited by this paper
• PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.

  2017cited by this paper
• Clinical development of anti‐CD19 chimeric antigen receptor T‐cell therapy for B‐cell non‐Hodgkin lymphoma

  2017cited by this paper
• Regional Delivery of Chimeric Antigen Receptor–Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain

  2017cited by this paper
• Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants

  2017cited by this paper
• Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models.

  2017cited by this paper
• Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer

  2017cited by this paper
• Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection

  2017cited by this paper
• Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.

  2017cited by this paper
• Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia.

  2016cited by this paper
• Driving CAR T-cells forward

  2016cited by this paper
• Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.

  2016cited by this paper
• Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

  2016cited by this paper
• CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

  2016cited by this paper
• Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.

  2016cited by this paper
• Adoptive cell transfer as personalized immunotherapy for human cancer

  2015cited by this paper
• Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T-lymphocytes

  2015cited by this paper
• T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

  2015cited by this paper
• Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice.

  2015cited by this paper
• Designing chimeric antigen receptors to effectively and safely target tumors.

  2015cited by this paper
• Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.

  2015cited by this paper
• Engineering CAR-T cells: Design concepts.

  2015cited by this paper
• IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo

  2015cited by this paper
• Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model

  2015cited by this paper
• Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.

  2015cited by this paper
• Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors

  2015cited by this paper
• 4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors

  2015cited by this paper
• A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer

  2015cited by this paper
• CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.

  2015cited by this paper
• The pharmacology of second-generation chimeric antigen receptors

  2015cited by this paper
• T Cell Engineering.

  2015cited by this paper
• Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity

  2015cited by this paper
• Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.

  2015cited by this paper
• Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL.

  2015cited by this paper
• Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition.

  2015cited by this paper
• Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer.

  2015cited by this paper
• Clinical Activity and Persistence of Anti-CD22 Chimeric Antigen Receptor in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

  2015cited by this paper
• ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

  2014cited by this paper
• T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.

  2014cited by this paper
• Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

  2014cited by this paper
• Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

  2014cited by this paper
• Chimeric antigen receptor T cells for sustained remissions in leukemia.

  2014cited by this paper
• Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma

  2014cited by this paper
• Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor

  2014cited by this paper
• Design and development of therapies using chimeric antigen receptor‐expressing T cells

  2014cited by this paper
• T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL

  2014cited by this paper
• Adoptive Therapy Using Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells to Manufacture T Cells Expressing CD19-Specific Chimeric Antigen Receptor

  2014cited by this paper
• The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity

  2014cited by this paper
• Thymic Stromal Lymphopoietin and Cancer

  2014cited by this paper
• Current concepts in the diagnosis and management of cytokine release syndrome.

  2014cited by this paper
• Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.

  2013cited by this paper
• Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity

  2013cited by this paper
• Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications.

  2013cited by this paper
• Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents.

  2013cited by this paper
• Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

  2013cited by this paper
• Microenvironmental regulation of tumor progression and metastasis

  2013cited by this paper
• Immunodominance: a pivotal principle in host response to viral infections.

  2012cited by this paper
• Targeted immunotherapy of cancer with CAR T cells: achievements and challenges

  2012cited by this paper
• CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

  2012cited by this paper
• OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells

  2012cited by this paper

• Genome-wide profiling the integration patterns with T7-PCR.

  2025cites this paper
• A Review of CAR T Cells and Adoptive T-Cell Therapies in Lymphoid and Solid Organ Malignancies

  2025influential citation
• Expanding the Horizons of CAR-T Cell Therapy: A Review of Therapeutic Targets Across Diverse Diseases

  2025cites this paper
• Cutting-Edge Technologies Illuminate the Neural Landscape of Cancer: Insights into Tumor Development.

  2025cites this paper
• Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools

  2025cites this paper
• Therapeutic mRNAs for cancer immunotherapy: From structure to delivery.

  2025cites this paper
• Immunogenicity of neoantigens: From CAR-T cell to various vaccines.

  2025cites this paper
• Overcoming toxicity challenges in CAR-T therapy: mechanisms and mitigation strategies

  2024cites this paper
• Recent advances in CAR‐T cell therapy for acute myeloid leukaemia

  2024cites this paper
• Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond

  2024cites this paper
• Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment

  2024cites this paper
• Simulation-Based Software Modeling of CAR T Cell Therapy Efficacy Against Solid Malignant Tumors

  2023cites this paper
• CAR-T Cells Immunotherapies for the Treatment of Acute Myeloid Leukemia—Recent Advances

  2023cites this paper